NCT05377268

The Use of Ultrasound Detection of Lipohypertrophy to Improve Glycemic Control

The Use of Machine Learning Detection of Lipohypertrophy to Improve Glycemic Variability

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University of British Columbia · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Lipohypertrophy is swelling of the fatty tissue located below the skin ("subcutaneous tissue") where many patients with diabetes inject their insulin. Lipohypertrophy can sometimes be felt as firm swelling, lumps or small bumps near insulin injection sites. Previous studies have shown that injecting insulin into areas of lipohypertrophy can affect how insulin is absorbed, and can increase insulin requirements in patients. New data suggest that lipohypertrophy can be detected using ultrasound technology. The ultrasonographic presence of changes to the subcutaneous tissue without swelling that can be felt ("subclinical lipohypertrophy") and the effect of injecting insulin into these sites is unknown. 100 people will participate in the Phase 1 of this study. In the second phase of the study, 40 patients identified with subclinical lipohypertrophy in Phase 1 will be asked to participate in the randomized study using crossover design by checking your glucose levels.

Detailed description

Purpose: In Phase 1: to use computer based technology to detect lipohypertrophy on portable ultrasound images. In Phase 2: to demonstrate that injecting insulin into areas to be free of lipohypertrophy will have better glucose control as compared to injecting into areas demonstrated to have lipohypertrophy. Eligibility: You can participate in this study if: * You have been diagnosed with Type 1 or Type 2 diabetes * You are currently using injection of insulin daily or insulin pump for at least 2 years * You are 19 years of age or older You should not participate in this study if: * You are taking a glucagon-like peptide medication * You are currently using a systemic steroid agent (e.g. prednisone) * You have history of a non-lipohypertrophic skin disease in the insulin injection area * You are not fluent in English (unless accompanied by a translator)

Conditions

• Diabetes Mellitus
• Lipohypertrophy

Interventions

Type	Name	Description
PROCEDURE	LH Protocol	Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy

Timeline

• Start date: 2023-03-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2022-05-17
• Last updated: 2024-05-09

Locations

1 site across 1 country: Canada